US FDA delays review of Allergan's Botox for migraines
This article was originally published in Scrip
Executive Summary
The US FDA has pushed back its decision timeline for approval of Allergan's Botox (botulinum toxin A) in the prevention and treatment of chronic migraine by three months, to October. The news was announced as the company presented its second quarter results on 2 August, which prompted a 6% rise in Allergan's share price, to $64.72 on the NYSE.